Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome

Autoimmunity Reviews

Volumn 11, Issue 5, 2012, Pages 330-334

  Efe, Cumali ^a   Ozaslan, Ersan ^b   Kav, Taylan ^a   Purnak, Tugrul ^b   Shorbagi, Ali ^a   Ozkayar, Ozgür ^a   Berlot, Alexandra Heurgue ^c   Sökmensuer, Cenk ^a   Muratori, Paolo ^d  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Numune Research and Education Hospital ^*  (Turkey)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Autoimmune hepatitis; Budesonide; Liver fibrosis; Overlap syndrome; Prednisone; Primary biliary cirrhosis; Steroid side effects

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BUDESONIDE; PREDNISONE;

ACNE; ADULT; ADVERSE DRUG REACTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BUFFALO HUMP; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIRSUTISM; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; MALE; MOON FACE; OUTCOME ASSESSMENT; OVERLAP SYNDROME; PRIMARY BILIARY CIRRHOSIS; REMISSION; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SKIN ALLERGY; STRIA; TREATMENT DURATION; WEIGHT GAIN;

ADULT; AGED; BUDESONIDE; FEMALE; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857500754     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.09.006     Document Type: Review

References (25)

1. Manns M.P., Czaja A.J., Gorham J.D., Krawitt E.L., Mieli-Vergani G., Vergani D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
2. Sousa G.M., Oliveira R.C., Pereira M.M., Paraná R., Sousa-Atta M.L., Atta A.M. Autoimmunity in hepatitis C virus carriers: involvement of ferritin and prolactin. Autoimmun Rev 2011, 10:210-213.
3. Bjornsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040-2048.
4. Ramos-Casals M., Ayala M.M., Brito-Zerón P., Callejas J.L., Caminal-Montero L., Camps M.T., et al. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193.
5. Santodomingo-Garzon T., Swain M.G. Role of NKT cells in autoimmune liver disease. Autoimmun Rev 2011, 10.1016/j.autrev.2011.06.003.
6. Oliveira L.C., Porta G., Marin M.L., Bittencourt P.L., Kalil J., Goldberg A.C. Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev 2011, 10:189-193.
7. Oikonomou K.G., Zachou K., Dalekos G.N. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev 2011, 10:389-396.
8. Yeoman A.D., Longhi M.S., Heneghan M.A. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther 2010, 31:771-787.
9. Muratori L., Muratori P., Granito A., Pappas G., Cassani F., Lenzi M. Current topics in autoimmune hepatitis. Dig Liver Dis 2010, 42:757-764.
10. Baven-Pronk A.M., Coenraad M.J., van Buuren H.R., de Man R.A., van Erpecum K.J., Lamers M.M., et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011, 34:335-343.
11. Tannous M.M., Cheng J., Muniyappa K., Farooq I., Bharara A., Kappus M., et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 2011, 34:405-407.
12. Danielsson A., Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994, 8:585-590.
13. Csepregi A., Rocken C., Treiber G., Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006, 12:1362-1366.
14. Zandieh I., Krygier D., Wong V., Howard J., Worobetz L., Minuk G., et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008, 22:388-392.
15. Czaja A.J., Lindor K.D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000, 119:1312-1316.
16. Wiegand J., Schuler A., Kanzler S., Lohse A., Beuers U., Kreisel W., et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005, 25:927-934.
17. Manns M.P., Woynarowski M., Kreisel W., Lurie Y., Rust C., Zuckerman E., et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010, 139:1198-1206.
18. Hennes E.M., Zeniya M., Czaja A.J., Parés A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
19. Chazouilleres O., Wendum D., Serfaty L., Montembault S., Rosmorduc O., Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
20. Brattsand R., Thalén A., Roempke K., Källström L., Gruvstad E. Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. J Steroid Biochem 1982, 16:779-786.
21. Clissold S.P., Heel R.C. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984, 28:485-518.
22. Hempfling W., Grunhage F., Dilger K., Reichel C., Beuers U., Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early-and late-stage primary biliary cirrhosis. Hepatology 2003, 38:196-202.
23. Sherman I.A., Pappas S.C., Fisher M.M. Hepatic microvascular changes associated with development of liver fibrosis and cirrhosis. Am J Physiol 1990, 258:460-465.
24. Björnsson E., Talwalkar J., Treeprasertsuk S., Neuhauser M., Lindor K. Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. Clin Gastroenterol Hepatol 2011, 9:57-63.
25. Lohse A.W., Gil H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J Hepatol 2011, 54:837-839.